Ethicon builds women’s health business
This article was originally published in The Gray Sheet
Executive Summary
Johnson & Johnson/Ethicon completed its acquisition of uterine fibroid treatment developer Vascular Control Systems on May 9. Ethicon picks up Flostat, which is a minimally invasive alternative for uterine artery occlusion, and Cstat, a guided hemostat to control blood loss during open surgeries. On May 11, the J&J division announced it had received a CE mark for its female stress urinary incontinence treatment TVT Secur. The device, which can be implanted under local anesthesia, uses J&J's Prolene mesh to create a mid-urethral sling...